The Immune Response Corporation
The Immune Response Corporation (Immune Response Biopharma) is a privately held firm described as specializing in autoimmune and infectious disease drug discovery, headquartered in Atlantic City, United States, with 11-50 employees. Its public website offers only a contact form and email signup with no disclosed products, pipeline, or business model.
- Company typePrivate
- Founded2011
- HeadquartersAtlantic City, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
The Immune Response Corporation firmographics
Firmographics- Name
- The Immune Response Corporation
- Legal name
- Immune Response Biopharma
- Website
- https://immuneresponsebiopharma.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- The Immune Response Corporation (Immune Response Biopharma) is a privately held firm described as specializing in autoimmune and infectious disease drug discovery, headquartered in Atlantic City, United States, with 11-50 employees. Its public website offers only a contact form and email signup with no disclosed products, pipeline, or business model.
- Ownership category
- akta.pro rank
The Immune Response Corporation industry classification
Industry- Product category
- Drug Discovery & Pharmaceutical Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where The Immune Response Corporation is headquartered
LocationHeadquarters
- HQ city
- Atlantic City
- HQ country
- United States
- HQ region
- North America
Markets served
The Immune Response Corporation business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Marketing channels1 record
The Immune Response Corporation product offering
Product offeringCore offering
The Immune Response Corporation is a biopharmaceutical research firm specializing in drug discovery for auto-immune and infectious diseases. The company focuses on immune health solutions, operating as a privately held research entity with 11-50 employees based in Atlantic City, United States. Its public-facing materials emphasize "empowering immune health solutions" without disclosing specific named drug candidates, platforms, or contracted service offerings.
Product overview
Immune Response Biopharma is a company focused on immune health solutions. The source website provides minimal detail about its specific product portfolio or service offerings beyond a general emphasis on 'empowering immune health.' No named products, modules, or distinct service offerings are described in the available source content.
Differentiator
Problem solved
Functional benefit
Companies that use The Immune Response Corporation
Customer profileIdeal customer profiles1 record
The Immune Response Corporation technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
The Immune Response Corporation partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights2 records
The Immune Response Corporation competitors and assessment
Company assessmentBroad incumbents
- AbbVie: Global biopharmaceutical company with leading autoimmune franchises (Humira, Skyrizi, Rinvoq) and active infectious disease research; relevant broad incumbent dominating the autoimmune therapeutic area.
- Regeneron Pharmaceuticals: Large biopharmaceutical company with major franchises in immunology/inflammation (Dupixent) and infectious disease antibodies; serves as the broad incumbent whose capabilities set the benchmark in the same therapeutic categories.
Direct peers
- AnaptysBio: Clinical-stage antibody discovery company with a focus on immunology and inflammation; comparable as an immunology-focused drug discovery firm leveraging antibody technology.
- Vir Biotechnology: Clinical-stage immunology and infectious disease company developing antibody-based therapeutics for serious infections and autoimmune conditions; directly comparable as a focused immunology/infectious disease drug discovery and development company.
- Arcturus Therapeutics: RNA-based therapeutics company with programs spanning infectious disease vaccines and immunology; comparable as a small-to-mid biotech pursuing immunology and infectious disease indications.
- AbCellera Biologics: Antibody discovery platform company focused on infectious disease and immunology; directly comparable as an immunology/infectious disease drug discovery firm built on antibody engineering capabilities.
- Alpine Immune Sciences: Clinical-stage biotechnology company developing protein-based immunotherapies for autoimmune and inflammatory diseases; directly comparable as a focused autoimmune/inflammation drug discovery and development company.
Emerging players
- Schrödinger: Computational drug discovery company with programs across immunology and infectious disease; comparable as a technology-enabled small/mid-cap drug discovery firm operating in overlapping therapeutic areas.
- Generate Biomedicines: Biotechnology company using generative biology to program novel protein therapeutics across immunology and infectious disease; comparable as a next-generation drug discovery platform intersecting the same therapeutic areas.
- Zenas BioPharma: Clinical-stage biopharmaceutical company developing immunology-based therapies for autoimmune diseases; comparable as a focused autoimmune drug developer, with more advanced clinical-stage programs than the subject.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key highlights4 records
Customer concentration
The Immune Response Corporation social profiles
Digital presenceThe Immune Response Corporation financial estimates
Financial estimateRevenue estimate
Valuation estimate
The Immune Response Corporation leadership team
Management profileNumber of profiles
The Immune Response Corporation funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The Immune Response Corporation M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The Immune Response Corporation
What does The Immune Response Corporation do?
The Immune Response Corporation is a biopharmaceutical research firm specializing in drug discovery for auto-immune and infectious diseases. The company focuses on immune health solutions, operating as a privately held research entity with 11-50 employees based in Atlantic City, United States. Its public-facing materials emphasize "empowering immune health solutions" without disclosing specific named drug candidates, platforms, or contracted service offerings.
Is The Immune Response Corporation a public or private company?
The Immune Response Corporation is a private company. It is classified as unknown and is currently operating.
When was The Immune Response Corporation founded?
The Immune Response Corporation was founded in 2011. It employs 11 to 50 people.
Where is The Immune Response Corporation based?
The Immune Response Corporation is headquartered in Atlantic City, United States, in the North America region.
Who are The Immune Response Corporation's main competitors?
Broad incumbents on record are AbbVie and Regeneron Pharmaceuticals. Direct peers are AnaptysBio, Vir Biotechnology, Arcturus Therapeutics, AbCellera Biologics and Alpine Immune Sciences. Emerging players are Schrödinger, Generate Biomedicines and Zenas BioPharma.
Does The Immune Response Corporation have an API?
No public API is recorded for The Immune Response Corporation.
What industry is The Immune Response Corporation in?
The Immune Response Corporation's product category is Drug Discovery & Pharmaceutical Research Services. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 541714 and its SIC code is 2834.